Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.
SinoMab BioScience Limited announced positive topline results from its Phase 1b clinical trial of SM17 in China for treating moderate-to-severe atopic dermatitis. The trial demonstrated significant efficacy in pruritus reduction and skin clearance, with no serious adverse events reported, positioning SM17 as a promising treatment option in the competitive dermatology market.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, focusing on the development of therapeutic antibodies for the treatment of various diseases, including autoimmune disorders. The company is engaged in research and development activities to advance its pipeline of innovative biologic products.
YTD Price Performance: 16.51%
Average Trading Volume: 193,715
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.39B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.